The U.S. Food and Drug Administration approved Krystexxa (pegloticase) for the treatment of gout patients. The drug was developed using Israel’s Bio-Technology General’s expertise in production and purification of recombinant proteins for parenteral use.
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm225810.htm